GEN Exclusives

More »

GEN News Highlights

More »
Mar 31, 2010

GSK’s BPH Therapy Receives European Clearance

  • GlaxoSmithKline’s (GSK) benign prostatic hyperplasia (BPH) treatment, Duodart®, received European regulatory clearance via the decentralized procedure. The once-daily drug comprises a fixed-dose combination of dutasteride and tamsulosin. It is indicated for treating moderate-to-severe symptoms of BPH and reducing the risk of acute urinary retension and surgery in relevant patients.

    Germany is acting as the Reference Member State for pan-European clearance. GSK expects national licenses to be granted in EU member states during the course of this year, with the first launches due in the next few months.

    European approval for Duodart was based on data from the CombAT trial, which showed that treatment using the dutasteride-tamsulosin combination provided patients with significantly better and more long-lasting symptom improvements in comparison with tamsulosin monotherapy. Duodart also reduced the risk of BPH complications by 66% in comparison with tamsulosin alone and by 20% compared with dutasteride monotherapy.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »